Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2012-12-06 (13 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: NIELLES-LES-BLEQUIN (62380), Pas-de-Calais
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMANIELLES : revenue, balance sheet and financial ratios
SELARL PHARMANIELLES is a French company
founded 13 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in NIELLES-LES-BLEQUIN (62380),
this company of category PME
shows in 2025 a net income positive of 65 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMANIELLES (SIREN 789810942)
Indicator
2025
2024
2023
2022
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
65 443 €
62 489 €
123 993 €
128 652 €
131 278 €
147 526 €
122 096 €
148 431 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMANIELLES generates positive net income of 65 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 148 k€ -> 65 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
65 443 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 14%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
14.367%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
76.813%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2022
2023
2024
2025
Debt ratio
222.549
155.361
109.722
82.106
44.005
31.024
22.601
14.367
Financial autonomy
27.09
35.045
42.84
48.332
60.339
68.195
72.427
76.813
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
14.372025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Good-5 pts over 3 years
In 2025, the debt ratio of SELARL PHARMANIELLES (14.37) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
76.81%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Excellent
In 2025, the financial autonomy of SELARL PHARMANIELLES (76.8%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 352.41. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2022
2023
2024
2025
Liquidity ratio
340.305
333.067
351.312
320.521
283.475
370.415
361.922
352.409
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
352.412025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Excellent
In 2025, the liquidity ratio of SELARL PHARMANIELLES (352.41) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Positioning of SELARL PHARMANIELLES in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMANIELLES is estimated at
1 039 569 €
(range 705 457€ - 1 631 228€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
705k€1039k€1631k€
1 039 569 €Range: 705 457€ - 1 631 228€
NAF 5 année 2025
Valuation method used
Net Income Multiple
65 443 €
×
15.9x
=1 039 570 €
Range: 705 457€ - 1 631 228€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMANIELLES with other companies in the same sector:
Frequently asked questions about SELARL PHARMANIELLES
What is the revenue of SELARL PHARMANIELLES ?
The revenue of SELARL PHARMANIELLES is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMANIELLES profitable?
Yes, SELARL PHARMANIELLES generated a net profit of 65 k€ in 2025.
Where is the headquarters of SELARL PHARMANIELLES ?
The headquarters of SELARL PHARMANIELLES is located in NIELLES-LES-BLEQUIN (62380), in the department Pas-de-Calais.
Where to find the tax return of SELARL PHARMANIELLES ?
The tax return of SELARL PHARMANIELLES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMANIELLES operate?
SELARL PHARMANIELLES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart